Drugs / lysine-3,4-methylenedioxyamphetamine
lysine-3,4-methylenedioxyamphetamine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04847206 | Dec 2021 → Jun 2024 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lysine-3,4-methylenedioxyamphetamine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04847206 ↗ |
| Modality | Small molecule | “Lysine-conjugated amphetamines slowly release active amphetamine once absorbed, suggesting pharmaceutical strategies to enhance tolerability and reduce abuse potential.” PMID 40999236 ↗ Sep 2025 |